In patients with large coronary vessels and ACC/AHA type B2/C complex lesions, a DCB-only strategy demonstrated comparable but not superior 3-year outcomes compared with newer-generation DES, suggesting no procedural simplification advantage with DCB-only treatment.
Abstract
Accumulating evidence suggests that DCB may achieve clinical outcomes comparable to DES, even in large coronary arteries and selected complex lesion subsets. However, the definition of “complex PCI” remains heterogeneous, and direct long-term comparisons between DCB-only strategies and newer-generation DES in anatomically complex large-vessel lesions are limited.
To compare 3-year clinical outcomes between a DCB-only strategy and newer-generation DES in patients with large (≥3.0 mm) coronary arteries and complex lesions defined as ACC/AHA type B2/C.
We retrospectively analyzed consecutive patients undergoing PCI between January 2018 and December 2023. Inclusion criteria were: large coronary vessels (≥3.0 mm), and complex lesions (ACC/AHA type B2 or C). Patients with in-stent restenosis or acute coronary syndrome were excluded. After propensity score matching, 113 patients treated with DCB were compared with 113 patients treated with newer-generation DES. The primary endpoint was target lesion failure (TLF), defined as cardiac death, target vessel myocardial infarction, or target lesion revascularization at 3 years. Secondary endpoints included all-cause death, cardiac death, target vessel revascularization (TVR), and target lesion revascularization (TLR). Procedural characteristics were also assessed.
Median follow-up duration was 1223 ± 690 days. At 3 years, cumulative TLF was numerically lower in the DCB group compared with the DES group (6.0% vs. 11.3%), but the difference did not reach statistical significance (log-rank p=0.159). The cumulative incidences of all-cause death, cardiac death, TVR, and TLR were comparable between groups. Procedural parameters, including contrast volume, procedure time, and fluoroscopy time, were similar between strategies, suggesting no procedural simplification advantage with DCB-only treatment.
In patients with large coronary vessels and ACC/AHA type B2/C complex lesions, a DCB-only strategy demonstrated comparable but not superior 3-year outcomes compared with newer-generation DES. Lesion complexity alone may not be sufficient to guide device selection. Instead, patient-specific factors—such as bleeding risk or the desire to avoid permanent metallic implantation—may play a more decisive role when considering a DCB-only strategy. A more patient-centered approach, rather than lesion morphology alone, may better inform optimal device selection in complex PCI.
Drug-coated balloon (DCB) has emerged as potential alternative to drug-eluting stents (DES) in specific lesion subsets for de novo coronary lesions. However, evidence supporting DCB in severely calcified lesions remains limited. Quantitative flow ratio (QFR) is a noninvasive quantitative tool for evaluating post-...
Q. Qin, L. Chen, Ren-De Xu et al.· European Heart Journal· 0 citations
Drug-coated balloons (DCB) are established therapy for coronary in-stent restenosis and are increasingly used in small-vessel disease, where they showed non-inferiority to DES in randomized trials such as BASKET-SMALL 2. Current ESC and international consensus documents primarily frame DCB as a strategy for ISR a...
L. Hamann, D. Faria, J. Pereira et al.· European Heart Journal· 0 citations
The medium-term clinical outcome following the use of a DCB only strategy in large vessel in ACS patient population was comparable to a DES only strategy, which was comparable to a DES only strategy.
H. Khan, M. Egred, M. Alkhalil et al.· European Heart Journal· 0 citations
For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
Wen-Jie Wang, Hong-Fei Si, L. Li et al.· Reviews in cardiovascular me...· 0 citations
AIM
Coronary artery calcification presents major challenges during PCI, including device deliverability, suboptimal lesion preparation, impaired stent expansion, increased restenosis, stent thrombosis and mortality. Drug-coated balloons (DCB) offer a stent-less alternative, but evidence in de novo calcified lesions is...
Rajkumar Natarajan, N. Corballis, I. Merinopoulos et al.· American Journal of Cardiolo...· 0 citations
Drug-coated balloon (DCB)-based strategies are increasingly explored as an alternative or adjunct to drug-eluting stent (DES) implantation to reduce permanent metal burden. However, real-world data on the utilization and safety of DCB-based strategies in acute coronary syndrome (ACS) remain limited.
To eva...
F. Rode, A. Jordan, M. Radić et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.